The earliest identified case by symptom onset, reported with an onset date of December 1, 2019, had no epidemiological link to the Huanan market, and no link was found between that patient and later cases.

Verbatim in the first clinical series (COV-E003) as a statement of what that publication reports. The onset date and index status are disputed in later reporting, which is why the claim is framed as the publication's account.

Verified verbatim as what the first clinical series reports (COV-E003). The date and index status are contested elsewhere, which is why the claim is framed as the publication's statement.

Verbatim in the first clinical series as that publication's own statement (COV-E003). The date and index status are disputed elsewhere, which the claim's framing already absorbs.

The first published clinical series (Huang 2020) explicitly documents a December 1, 2019, index case with no epidemiological link to the Huanan market. This observation aligns cleanly with models requiring either upstream spillover or an earlier unlinked research infection. The strongest opposing consideration is that early exposure histories in clinical series are frequently incomplete, and later reporting has heavily contested this specific patient's status and onset date as the true earliest case.

The earliest published clinical series explicitly documents a December 1, 2019 onset for the first patient and states no epidemiological link to the Huanan market or later cases was found. The claim accurately reflects what the published clinical record states. The strongest opposing consideration is that the patient's actual onset date and status as the true earliest case have been disputed in later, separate reporting that cannot currently be adjudicated.

The earliest published clinical series by Huang et al. explicitly reports that the earliest identified patient had a December 1 onset date and no epidemiological link to the market. This observation provides plausible evidence for an upstream spillover or non-market index event. The strongest opposing consideration is that a single patient's exposure history is weak evidence, and the identification of this specific patient as the true earliest case has been heavily disputed.

COV-E003 quotes the Lancet clinical series verbatim: the first identified patient had onset on 1 December 2019, lacked a market link, and no epidemiological link to later cases was found; the claim is explicitly framed as “what the study reports,” which the evidence clearly supports. The main opposing consideration is that later reporting has questioned whether this was truly the earliest case and whether the onset date is accurate, matters this dossier does not independently resolve.

The Huang et al. clinical series states verbatim that the first identified patient's symptom onset was 1 December 2019, that he had no Huanan market exposure, and that no epidemiological link was found to later cases (COV-E003). While later reporting has questioned whether this was truly the earliest case and whether the onset date is exact, this claim is explicitly framed as what the paper reports, and on that narrow reading it is well supported.

The Huang clinical series explicitly states that the earliest identified case by onset date had no market exposure and no epidemiologic links to later cases; the claim is carefully worded as “what the publication states.” The main counterpoint is that later reporting has challenged whether this was truly the earliest case and whether the onset date is accurate, so it should not be over‑interpreted as establishing the true index case.

Huang 2020 states verbatim that the first identified patient's symptom onset was 1 December 2019, that none of his family members developed fever or respiratory symptoms, and that no epidemiological link was found between that patient and later cases. The claim is graded as a report of what that publication records, which is the form the case file itself adopts. The strongest opposing consideration is that a single early clinical-series exposure history is weak evidence about outbreak origin, the same paper reports that two-thirds of the series had direct market exposure, and later reporting has disputed this patient's status and onset date — a dispute the provided record has not adjudicated.

Huang et al. state verbatim that the symptom onset date of the first identified patient was 1 December 2019, that none of his family developed symptoms, and that no epidemiological link was found between that patient and later cases. The claim is graded as a report of that published series, including the paper's own onset date, not as a settled reconstruction of the index infection. The same paper reports that two-thirds of the 41 patients had direct market exposure, so the unlinked earliest case sits inside a market-centered cluster rather than replacing it. Strongest opposing consideration: later reporting not adjudicated in this file disputes whether this patient was in fact the earliest case and whether the December 1 onset date is correct, and a single early clinical history is weak evidence about the outbreak's origin.

The first published clinical series of 41 patients states verbatim that the earliest identified case had symptom onset on 1 December 2019, that none of his family members developed symptoms, and that no epidemiological link was found between that patient and later cases. The claim as worded records what that paper reports, not a settled reconstruction of the index infection, and the same paper reports that 27 of 41 patients had been exposed to the market. The strongest opposing consideration is that later reporting has disputed this patient's status as earliest and the December 1 onset date, a dispute this file does not adjudicate, and a single case's reported exposure history is weak evidence about the outbreak's origin.

Assessed as stated — what the first clinical series reports — the claim is verified verbatim: the December 1, 2019 onset date and the sentence that no epidemiological link was found between the first patient and later cases both appear in the Lancet paper. The claim is carefully framed as a record of publication rather than a settled fact about the outbreak, and on that footing it is well supported. The strongest opposing consideration is that later reporting has disputed both this patient's status as the earliest case and the onset date, disputes this case file has not adjudicated, and a single exposure history from a 41-patient series is weak origin evidence regardless. Confidence is moderate because the claim's truth is bibliographic while its referent is contested.

Both load-bearing sentences — the December 1, 2019 onset date and the absence of any epidemiological link to later cases — are verified verbatim in the first clinical series, and the claim is honestly framed as what that publication states. The strongest opposing consideration is that later reporting has disputed whether this patient was genuinely the earliest case and whether the onset date is correct, a dispute this record does not adjudicate; a single case's recalled exposure history is also weak evidence about an outbreak's origin. As a claim about the published record it is solid; its diagnostic weight is modest, since the same paper reports two-thirds of the series had direct market exposure.

The claim as framed is bibliographic — it records what the first clinical series states — and the onset date and no-link sentences are verified verbatim in the Lancet paper. Assessed as stated, it is solid. The strongest opposing consideration is that the patient's status as the true earliest case and the December 1 onset date have been contested in later reporting this case has not adjudicated, so the claim's narrow framing is doing real protective work. Its diagnosticity for origin is modest in any case: an unlinked earliest case is compatible with upstream spillover, a non-market index, or an unascertained market chain.

Both halves are verbatim in the Lancet series: the December 1 onset date and the statement that no epidemiological link was found between that patient and later cases. The claim is framed as what the publication states, which is the defensible form. The strongest opposing consideration is that the identification of this patient as the earliest case, and the onset date itself, have been contested in later reporting this case has not adjudicated — and that a single case's reported exposure history in an early series is weak evidence about outbreak origin either way, particularly when two-thirds of the same series had market exposure.

As worded — what the first clinical series reports — the claim is verified verbatim, including the sentence that no epidemiological link was found between the first patient and later cases. The strongest opposing consideration is that the underlying facts, not the publication, are disputed: the identity of the earliest case and the December 1 onset date were later contested, and this ledger has not adjudicated that. The same paper also records that 27 of 41 early patients had direct market exposure, so the claim's evidential pull against market-centred spillover is modest. Confidence is moderate rather than high because the claim's value depends on a single patient's reported exposure history in a hastily assembled series.

Read as a claim about what the first published clinical series states, this is verbatim and uncontested: onset December 1, 2019, no market link, no epidemiological link to later cases. The strongest opposing consideration is that the underlying fact — that this really was the earliest case, on that date — has been disputed in later reporting the ledger explicitly declines to adjudicate, and a single reported exposure history in a rapidly assembled January 2020 series is fragile evidence. Note also that the same paper reports 27 of 41 patients with direct market exposure, so it is not net evidence against market centrality. I grade the claim as worded; had it asserted the underlying fact rather than the publication's statement, I would drop it to provisionally_supported.

Verified verbatim as a statement of what the clinical series reports. Framed as the publication's statement because the case's date and status are disputed elsewhere.

Verified verbatim as a statement of what the first clinical series reports (COV-E003). Its date and index status are disputed elsewhere, which is why the claim is framed as the publication's statement. No seat contests this.